Paul Damon & Associates, Inc. Eli Lilly & CO Transaction History
Paul Damon & Associates, Inc.
- $162 Billion
- Q1 2025
A detailed history of Paul Damon & Associates, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Paul Damon & Associates, Inc. holds 255 shares of LLY stock, worth $229,232. This represents 0.13% of its overall portfolio holdings.
Number of Shares
255Holding current value
$229,232% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding LLY
# of Institutions
4,348Shares Held
759MCall Options Held
10.2MPut Options Held
11.4M-
Lilly Endowment Inc Indianapolis, IN96MShares$86.3 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA74.2MShares$66.7 Billion1.03% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$59.2 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.3MShares$46.1 Billion26.72% of portfolio
-
State Street Corp Boston, MA34.3MShares$30.8 Billion1.07% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $854B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...